Syndromic agammaglobulinaemia (Q88427): Difference between revisions

← Older edit

@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/1049161944
@@ Property / Canonical URI: https://id.who.int/icd/entity/1049161944 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:ID_1049161944
@@ Property / CURIE: CID11:ID_1049161944 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-ID_1049161944
@@ Property / Canary Token: dki-india-ID_1049161944 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 14:39, 15 August 2026

This is a rare X-linked genetic disorder discovered in 1952 that affects the body's ability to fight infection. XLA is an X-linked disorder, and therefore is much more common in males. XLA patients do not generate mature B cells, which manifests as a complete lack of antibodies in their bloodstream.

Language	Label	Description	Also known as
default for all languages	ID_1049161944
English	Syndromic agammaglobulinaemia	This is a rare X-linked genetic disorder discovered in 1952 that affects the body's ability to fight infection. XLA is an X-linked disorder, and therefore is much more common in males. XLA patients do not generate mature B cells, which manifests as a complete lack of antibodies in their bloodstream.